FAQs
In this FAQ section, you'll find answers about our mission, why Texas plays a crucial role in the psychedelic policy landscape, our legislative efforts, and the broader impact of psychedelic therapies.
Texans for Greater Mental Health (T4GMH) is a grassroots nonprofit organization committed to raising awareness and understanding of psychedelic therapies. Our focus is on research and expanding access to innovative mental health solutions. We empower individuals and policymakers with knowledge about these transformative medicines, advocating for a research-first, science-led approach to psychedelic policy reform.
Texas is uniquely positioned to drive both state and national psychedelic policy reform. With a large budget surplus, strong leadership backing psychedelic initiatives, and top-tier researchers at flagship institutions, Texas is forging the way for groundbreaking mental health solutions.
By nurturing state leadership, engaging policymakers, and educating the public, Texas is not only advancing its own policies but also setting the stage for national and federal reform. True progress in psychedelic policy must be led by Texans, with a vision that extends far beyond state borders.
Our mission is to improve mental health outcomes by advancing the development and acceptance of psychedelic therapies through education, engagement, advocacy, and policy reform.
We strive to ensure these promising treatments are accessible, safe, and integrated into the healthcare system, providing relief for individuals suffering from severe mental health conditions.
House Bill 1802 was passed in the 2021 Texas Legislative Session, establishing a clinical trial for the use of psilocybin to treat PTSD in Veterans. It was a watershed bill for a few reasons:
-
It was the first public funding for psychedelic research since the Controlled Substances Act
-
It was the first psychedelic research legislation passed in the United States
-
It established the first psilocybin for PTSD clinical trial in the United States
-
It created a template for psychedelic policy that has now been used across the country
Baylor College of Medicine and Dr. Lynette Avrill, T4GMH Advisory Board Member, is conducting the trial (currently underway) in collaboration with HHSC and in partnership with a military Veterans hospital or a medical center that provides medical care to Veterans.
The study also includes a literature review of the efficacy and access to psilocybin, MDMA, and ketamine in the United States.
-
Texans for Greater Mental Health has partnered with the Texas Ibogaine Initiative to secure $50 million in state funding for a first-of-its-kind Texas-based FDA-approved clinical trial. This initiative seeks to advance research on Ibogaine as a treatment for Opioid Use Disorder and co-occurring conditions, paving the way for groundbreaking therapies and expanding access to innovative mental health solutions.
You can learn more about the Texas Ibogaine Initiative by visiting:
https://www.reid.foundation/texas-ibogaine-initiative
and watching this Joe Rogan Experience podcast episode:
